trial

Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics

NCTId NCT01081769
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 769 (actual)
Sponsored by Janssen-Cilag Farmaceutica Ltda.
Primary completion 2013-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
769 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2010-02
Primary completion
2013-02
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Paliperidoneoral antipsychotics

Sponsors

Janssen-Cilag Farmaceutica Ltda.Lead Sponsor

Sites

0 total

Linked catalysts

1
Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsy — primary completion2013-02

Facts & assertions

4 sourced
Enrollment
769
Phase
PHASE3
Primary Completion Date
2013-02
Status
COMPLETED
relationships
The graph out of here
drug
Paliperidone
drug
oral antipsychotics
drug
lead_sponsor
Janssen-Cilag Farmaceutica Ltda.
company
indication
Schizophrenia
indication
Schizophrenia
indication
Recurrence
indication